X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/goodrx-offer-sanofis-insulin-injection-only-35-2023-10-19/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761201
https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-cut-price-its-most-prescribed-insulin-by-78-us-2023-03-16/
https://www.contractpharma.com/contents/view_breaking-news/2023-02-23/glooko-sanofi-partner-for-solostar-pen-connectivit/?widget=listSection
https://www.biopharmadive.com/news/lilly-rezvoglar-insulin-interchangeable-fda-approval/636959/
https://endpts.com/lilly-wins-fda-approval-for-second-interchangeable-insulin-biosimilar/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761215
https://pink.pharmaintelligence.informa.com/PS147023/Pharma-Readies-For-Price-Caps-On-Glargine-Teneligliptin-Lenalidomide-In-India
https://www.globenewswire.com/news-release/2022/09/16/2517875/0/en/Skylight-Health-Announces-Series-A-Preferred-Stock-Cash-Dividend.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/diabetes-patented-tb-hiv-drugs-enter-essential-list/articleshow/94185393.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206538
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/eris-lifesciences-enters-licensing-deal-with-biocon-for-insulin-glargine/articleshow/93375874.cms
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-3-2022-1659944441.pdf
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-pharmaceuticals-inc-viatris-company-issues-voluntary-nationwide-recall-one-batch-insulin
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208673
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-4-2022-1651646484.pdf
https://www.fiercepharma.com/pharma/mysterious-case-viatris-and-missing-insulin-label-deepens-after-second-semglee-recall-2022
https://www.pharmacompass.com/pdf/news/mylan-pharmaceuticals-inc-a-viatris-company-issues-voluntary-nationwide-recall-of-one-batch-of-insulin-glargine-due-to-the-potential-for-a-missing-label-in-the-batch-1649915477.pdf
https://www.prnewswire.com/news-releases/lannett-initiates-pivotal-clinical-trial-for-biosimilar-insulin-glargine-301512139.html
https://www.fiercepharma.com/manufacturing/viatris-mylan-yanks-one-batch-diabetes-med-over-missing-label-fears
https://www.prnewswire.com/news-releases/lannett-announces-fda-completes-review-of-investigational-new-drug-ind-application-for-biosimilar-insulin-glargine-301465378.html
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mylan-pharmaceuticals-inc-viatris-company-conducting-voluntary-recall-one-batch-semgleer-insulin
https://www.practiceupdate.com/content/fda-approves-second-biosimilar-insulin-product-rezvoglar-insulin-glargine-aglr-nbsp/128694/7/8/2
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761215
https://www.centerforbiosimilars.com/view/the-top-5-biosimilar-articles-for-the-week-of-december-6
https://www.fiercepharma.com/pharma-asia/biocon-viatris-insulin-biosimilar-astrazeneca-china-performance-huahai-fda-warning-lift
https://www.moneycontrol.com/news/trends/health-trends/biocon-biologics-viatris-launch-biosimilar-insulin-glargine-in-us-7728091.html
https://www.biocon.com/docs/BBL_Viatris_Glargine_Prime_Therapeutics_statement.pdf
https://www.primetherapeutics.com/news/prime-therapeutics-backs-first-interchangeable-insulin-biosimilar-semglee/
https://www.europeanpharmaceuticalreview.com/news/164399/tirzepatide-maintains-ac1-and-weight-control-in-type-2-diabetes-patients/
https://www.biospace.com/article/lilly-diabetes-drug-continues-to-outperform-insulin-glargine-with-no-increased-heart-risks/?s=71
https://www.raps.org/news-and-articles/news-articles/2021/8/fda-approvals-roundup-semglee-saphnelo-uptravi
https://www.prnewswire.com/news-releases/nuevos-datos-sobre-las-insulinas-aspart-gl-asp-lispro-gl-lis-y-glargina-gl-gla--802413956.html
https://www.prnewswire.com/news-releases/new-data-on-phase-1-proposed-biosimilar-gan--lee-insulins-aspart-gl-asp-lispro-gl-lis-and-glargine-gl-gla-presented-at-the-american-diabetes-associations-81st-scientific-sessions-301324495.html
https://www.prnewswire.com/news-releases/mylan-and-biocon-biologics-announce-launch-of-semglee-insulin-glargine-injection-in-the-us-to-expand-access-for-patients-living-with-diabetes-301120824.html
https://economictimes.indiatimes.com/markets/expert-view/glargine-launch-in-us-opens-up-a-huge-opportunity-for-biocon-kiran-mazumdar-shaw/articleshow/77864864.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210605
https://www.expresspharma.in/latest-updates/biocon-and-mylan-receive-us-fda-approval-for-semglee-an-insulin-glargine-injection/
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-gets-us-fda-nod-to-launch-insulin-glargine/articleshow/76333456.cms
https://www.prnewswire.com/news-releases/lannett-provides-update-on-clinical-advancement-of-biosimilar-insulin-glargine-following-fda-meeting-301074221.html
https://www.bigmoleculewatch.com/2020/06/03/ptab-issues-final-written-decisions-finding-most-claims-of-sanofis-lantus-patents-invalid/
https://www.raps.org/news-and-articles/news-articles/2020/2/teva-calls-on-fda-to-make-copaxone-a-biologic-as-p
https://www.biospectrumasia.com/news/30/15224/vista-eye-specialist-brings-vision-correction-to-new-level.html
https://www.fiercepharma.com/pharma/oncology-rare-diseases-told-story-big-pharma-strategy-2019-will-2020-be-same
https://www.biospace.com/article/fda-approves-sanofi-s-toujeo-for-pediatric-diabetes/?s=95
https://www.prnewswire.com/news-releases/positive-results-in-phase-3-trial-for-toujeo-in-children-and-adolescents-with-type-1-diabetes-300950052.html
https://www.fiercepharma.com/pharma/pharma-shares-slide-after-democrats-aggressive-drug-pricing-plan-leaks
Market Place
Share 
